Anyone care to interpret?|
FDA Cancels Myotrophin Advisory Panel Meeting
Monday, April 6 8:00 AM ET
WEST CHESTER, Pa., and EMERYVILLE, Calif., April 6 /PRNewswire/ -- Cephalon, Inc. (NASDAQ:CEPH) and Chiron Corporation (NASDAQ:CHIR) announced today that the U.S. Food and Drug Administration (FDA) has cancelled the Peripheral and Central Nervous System Drugs Advisory Committee meeting, scheduled for April 9, 1998, to allow the agency to continue its review of the companies' new drug application (NDA) seeking clearance to market MYOTROPHIN(R) (mecasermin) Injection for the treatment of ALS.
Cephalon, Inc., headquartered in West Chester, PA, is an international biopharmaceutical company that discovers, develops and markets products to treat neurological disorders.
Chiron Corporation, headquartered in Emeryville, Calif., is a leading global biotechnology company that combines diagnostic, vaccine and therapeutic strategies for controlling disease.
This news release may contain forward-looking statements that involve risks and uncertainties. A full discussion of Cephalon's operations and financial condition, including factors that may affect the company's business and future prospects, is contained in documents the company files with the SEC, such as form 10-Q and 10-K reports. These documents identify important factors that could cause the company's actual performance to differ from current expectations.